Modality
siRNA
MOA
BTKi
Target
GIP-R
Pathway
T-cell
Wet AMD
Development Pipeline
Preclinical
~Jul 2015
→ ~Oct 2016
Phase 1
~Jan 2017
→ ~Apr 2018
Phase 2
Jul 2018
→ Jun 2028
Phase 2Current
NCT04724095
1,053 pts·Wet AMD
2020-01→2026-08·Completed
NCT05598328
1,016 pts·Wet AMD
2018-07→2028-06·Recruiting
2,069 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-08-134mo awayPh2 Data· Wet AMD
2028-06-252.2y awayPh2 Data· Wet AMD
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P2
Recruit…
P2
Complet…
Catalysts
Ph2 Data
2026-08-13 · 4mo away
Wet AMD
Ph2 Data
2028-06-25 · 2.2y away
Wet AMD
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04724095 | Phase 2 | Wet AMD | Completed | 1053 | SRI-4 |
| NCT05598328 | Phase 2 | Wet AMD | Recruiting | 1016 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| TAK-2403 | Takeda | Phase 2 | WEE1 |